Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | XPO1 | O14980 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | RXRB | P28702 | 2/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16261285 | 0.91 | RAPGEF4 (0.46) | CES2ARMEN1KMT2AMAPT | |
| SCHEMBL14994029 | 0.89 | NOTUM (0.49) | CES2ARMEN1KMT2AMAPT | |
| SCHEMBL545622 | 0.89 | TSHR (0.43) | CES2ARMEN1KMT2AMAPT | |
| SCHEMBL548187 | 0.85 | GABRA1 (0.45) | ARMEN1KMT2AMAPTRXRA | |
| SCHEMBL16259688 | 0.85 | AR (0.39) | CES2ARMEN1KMT2AMAPT | |
| SCHEMBL4564009 | 0.83 | CES2 (0.48) | CES2ARMEN1KMT2AMAPT | |
| SCHEMBL15456420 | 0.83 | CES2 (0.41) | CES2ARMEN1KMT2AMAPT | |
| SCHEMBL27186725 | 0.83 | CES2 (0.55) | CES2ARMEN1KMT2AMAPT | |
| SCHEMBL29799797 | 0.83 | CES2 (0.55) | CES2ARMEN1KMT2AMAPT | |
| SCHEMBL29799650 | 0.82 | TACR1 (0.44) | CES2ARMEN1KMT2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3381886-A1 | A PROCESS FOR PRODUCING CARBOXYLIC ACIDS FROM TERTIARY ALCOHOLS UNDER CONTINUOUS FLOW | Helsinn Healthcare SA (CH) | 2018-10-03 | — | — | EP | disclosed |
| EP-1368295-B1 | PROCESS FOR THE MANUFACTURE OF PHENYLACETIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20130281729-A1 | CONTINUOUS METHOD FOR THE CARBONYLATION OF ALCOHOLS, IN PARTICULAR OF PHENYL ALCOHOLS | AET GROUP (FR) | 2013-10-24 | — | — | US | disclosed |
| EP-2651870-A2 | CONTINUOUS METHOD FOR THE CARBONYLATION OF ALCOHOLS, IN PARTICULAR OF PHENYL ALCOHOLS | Aet Group (FR) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080647-A2 | CONTINUOUS METHOD FOR THE CARBONYLATION OF ALCOHOLS, IN PARTICULAR OF PHENYL ALCOHOLS | AET GROUP (FR) | 2012-06-21 | — | — | WO | disclosed |
| CN-1235856-C | Process for preparing phenylacetic acid derivatives | HOFFMANN LA ROCHE (CH) | 2006-01-11 | — | — | CN | disclosed |
| CN-1491200-A | Process for manufacture of phenylacetic acid derivatives | - | 2004-04-21 | — | — | CN | disclosed |
| EP-1368295-A1 | PROCESS FOR THE MANUFACTURE OF PHENYLACETIC ACID DERIVATIVES | F. Hoffman-la Roche AG (CH) | 2003-12-10 | — | — | EP | disclosed |
| US-6531597-B2 | Reacting a halo substituted benzene with a ketone to form a hydroxyalkyl benzene that is carbonylated with a strong acid | HOFFMANN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020156313-A1 | Process for preparation of 2-phenyl acetic acid derivatives | HOFFMANN-LA ROCHE INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2002079134-A1 | PROCESS FOR THE MANUFACTURE OF PHENYLACETIC ACID DERIVATIVES | F. HOFFMANN-LA-ROCHE AG (CH) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156313-A1 | Process for preparation of 2-phenyl acetic acid derivatives | ALDH1A1, UGT1A1, PAH | CES2 1802/4885AR 1677/4885MEN1 1374/4885 |
| US-20130281729-A1 | CONTINUOUS METHOD FOR THE CARBONYLATION OF ALCOHOLS, IN PARTICULAR OF PHENYL ALCOHOLS | ADH1A, ADH5, ADH1C | CES2 40/4885AR 3578/4885MEN1 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.